In this regard, the detection of anti-ECP in our cohort may define a more precise patient group as all AEOSA+/ANCA− sera displaying both anti-EPX and anti-ECP reactivity appeared mainly in patients with either gastrointestinal tract inflammation and/or ankylosing spondylitis. The gene discussed is EPX; the disease is ankylosing spondylitis.